Sodium glycerophosphate, sold under the brand name Glycophos, is a medication used to supplement phosphate.[3][4] It is administered via intravenous infusion.[3][4]

Sodium glycerophosphate is an organic phosphate salt.[3][4]

It was approved for medical use in Australia in November 2019.[5][3][6]

It is an unapproved medication in the United States that was used as a substitute for inorganic phosphate during a drug shortage.[4]

Chemistry

The substance is a mixture of disodium glycerol 1- and 2-phosphates, which have different amounts of water of crystallization; the total amount is 5+1⁄2 H2O per glycerol phosphate molecule. It is a white to off-white powder which may or may not be crystalline, has no discernible odor and tastes salty. It melts at 98 to 100 °C (208 to 212 °F) and decomposes at 130 °C (266 °F). Aqueous solutions have a pH of about 9.5.[7]

References

  1. ^ "Glycophos APMDS". Therapeutic Goods Administration (TGA). 26 May 2022. Retrieved 10 March 2024.
  2. ^ "Australian Public Assessment Report for Sodium glycerophosphate (as hydrate)" (PDF). Therapeutic Goods Administration (TGA).
  3. ^ a b c d "ARTG Entry:312021 Glycophos Product Information" (PDF). Therapeutic Goods Administration (TGA). Retrieved 23 August 2020.
  4. ^ a b c d "Glycophos- sodium glycolate injection, solution". DailyMed. 16 January 2019. Retrieved 23 August 2020.
  5. ^ "Glycophos Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). Retrieved 23 August 2020.
  6. ^ "Summary for ARTG Entry:312021 Glycophos sodium glycerophosphate (as hydrate) 4.32 g/20 mL concentrated solution for injection ampoule". Therapeutic Goods Administration (TGA). Archived from the original on 18 April 2021. Retrieved 23 August 2020.
  7. ^ Hagers Handbuch der pharmazeutischen Praxis (in German). Vol. VI.A (4th ed.). Springer. 15 August 1977. pp. 91–92. ISBN 3-540-05123-6.


Allikas: https://en.wikipedia.org/wiki/Sodium_glycerophosphate
No tags for this post.